Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Palliative care is the care of people with a progressive, life-limiting illness. Since today people live longer with a cancer or another advanced progressive disease, they often experience fatigue. Research at the bedside aims to reduce symptoms and improve the quality of what is left of their life.

Q: What is palliative care?

BW: Palliative care is the care of people who have advanced progressive disease, a life limiting disease, where we look at the physical, psychological, social and spiritual aspects of how that affects them, and try to improve the quality of life for what there is left of their lives.

Q: Is palliative care different today than 5 or 10 years ago?

BW: Yes, when palliative care first started it was very much focusing on 'terminal care' if you like, the last few weeks of life. Then we got better at doing that and now we are involved at an earlier stage. But in the last 5 to 10 years, a lot of the patients that we look after are cancer related, and of course cancer has become a much more chronic disease - people are living longer with it but with symptoms and with psychological effects from it. We are also becoming much more involved with people with none cancer disease: people with heart failure, advanced chest diseases, liver disease, neurological diseases like multiple sclerosis and Parkinson's and so on. We are involved with basically anybody who is perhaps in their last year or years of life.

Q: What is the Sobell Study Centre?

BW: The Sobell Study Centre is the educational and research arm of the Sir Michael Sobell House, which is based on the Churchill Hospital site. Sobell House itself is a specialist palliative care service; it provides beds for patients who have specialist palliative care needs, and also has teams going out into the community and into the hospitals in order to support patients. The Study Centre provides the hub for education and research into palliative care.

Q: What are the major lines of research in palliative care?

BW: There are two particular areas where Oxford is concerned. One is in end of life care, so the experiences of people at the very end stage, but the other bigger area now is actually in fatigue.

Q: What is fatigue?

BW: Fatigue is the utter exhaustion that we have all experienced. The difference is that with this group of people, when they have had a rest it doesn't change their experience of fatigue, unlike you or I who will feel rested after we have had a good night's sleep for instance.

Q: Why does you line of research matter, why should we put money into it?

BW: Firstly fatigue is a very common problem; if we think that in the last year something like half a million people died in England, of whom a large proportion would have been living with disease for the last year of their life. Fatigue can be as common as anything up to 75% in people with cancer, if they are having chemotherapy and radiotherapy it is greater than that, about 60-80% in people with heart failure, same again in chest diseases.

For example, one of the patients I saw yesterday was a gentleman who had advanced liver disease and he has been trying to live a normal life. He went to visit his son as he does every weekend and I would like to quote to you what he said to me; "I felt very very tired. I couldn't keep awake and when I went to bed I couldn't sleep at all. And during the day time it was as if a cloud had come over me, I had to close my eyes and just fall asleep. I have got no energy; energy is completely sapped from me. I can't walk properly. I want to walk and I can do it with a stick but very very slowly and I am shattered at the end of that". Unlike you or I if we get fatigue we go to bed, we get up and we are rested. People with advanced disease don't. It is a very common problem and we don't have a lot of good ways of handling it.

Q: How does your research fit into translational medicine within the department?

BW: It is very much at the bedside. We have two projects going at the moment. One is a drug trial to try to develop a very simple and inexpensive drug to try and improve fatigue in these patients. We also have behavioural management, so with the help of an occupational therapist helping patients to find ways of managing the physical, psychological and emotional impact of fatigue on their lives. So that is, if you like, 'at the bedside' bit of it. But we are also interested in finding out the point at which fatigue becomes irreversible to see if we can come up with ways of stopping it from becoming irreversible. So unlike our usual 'bench to bedside', perhaps we are looking at 'bedside to bench' here.

Bee Wee

End of Life Care

Professor Bee Wee is the Head of Palliative Care Research and Development, based at Sir Michael Sobell House in Oxford. Her current lines of research include End of life care for people with incurable cancer and advanced non-malignant disease, Symptom management and Rehabilitation.

Read an interview published by BMJ in April 2015: Bee Wee, Determined, resourceful, considerate

More podcasts related to Cancer

Raghib Ali: INDOX Cancer Research Network

INDOX is a collaboration between Oxford and twelve leading cancer centres in India. It aims to develop effective and affordable cancer treatments in low and middle income countries, to improve the early detection of cancer, and to reduce the incidence of cancer by establishing the population specific risk factors.

Vincenzo Cerundolo: Cancer immunology

The development of therapeutic vaccines is more challenging. Current lines of research include the development of antibodies blocking inhibitory T cell signals, and the characterisation of adjuvants.

David Jackson: The Lymphatic System in Immunity and Cancer

Our lymphatic system protects us against pathogens: it collects micro-organisms and carries them to the lymph nodes where they will meet and activate T cells and B cells. Cancer cells also migrate to the lymph nodes, but instead of activating the immune system they actually suppress it. A better understanding of these mechanisms might help us better control the spread of tumours, and also block unwanted immune responses in autoimmune diseases, block tissue rejection and make vaccines more effective.

Tim Key: Role of Lifestyle and Diet in Cancer

We know that although smoking is still the most important cause of cancer, obesity and high intakes of alcohol increase the risk for several types of cancer. The role of diet in the development of cancer is much less clear, but there is a lot of evidence suggesting that diet does matter.

Patrick Pollard: Cancer Metabolism

Dr Pollard’s work is focused on a form of kidney cancer for which no effective therapy exists once it metastasizes. By integrating analyses of these cancer cells and novel models he hopes to provide insights into altered cancer metabolism and a real, innovative route into the design of therapies for various cancers.

Catherine Green: DNA replication and Cancer

The process of DNA replication is complex, and mistakes can lead to genome instability. Surveillance systems are not always successful which results in mutations that have the potential to inactivate genes or change their activity. This can lead to cancer, and many chemotherapeutic drugs are designed to disrupt DNA replication. A better understanding of these mechanisms can help us develop new drugs with reduced side effects.

Skirmantas Kriaucionis: Epigenetic modifications and cancer

Although all cells in our body have the same genome, they look different and perform different functions. Epigenetic modifications such as methylations ensure which sets of genes are expressed in specific cells and how this specificity is inherited. Cancer cells show particular epigenetic abnormalities which can be targeted for cancer therapies.

Ross Chapman: Repairing DNA damage

Whilst controlled DNA breaks allow for our vast repertoire of antibodies, DNA damage happening out of context can lead to cancer or predisposition to cancer. Recent developments in personalised medicine exploit the DNA repair weaknesses of cancer cells to selectively kill them. A better understanding of the underlying mechanisms can help develop innovative and targeted therapies.

John Christianson: Cleaning up misfolded proteins

Misfolded proteins can either create the loss of a cellular function, or escape degradation, causing aggregation diseases. Better knowledge of these mechanisms helps us understand the root cause of different kind of diseases, and also develop targets for therapeutic intervention.

Robert Gilbert: Targeting cancer mechanisms

Switching mechanisms within our cells are in part responsible for their development. MicroRNAs control a whole set of proteins associated with stem cell biology, particularly cancer stem cells. Targeting these components raises the potential for new anti-cancer therapeutics, which work by switching off protein production rather than inhibiting them later.

Translational Medicine

From Bench to Bedside

Ultimately, medical research must translate into improved treatments for patients. At the Nuffield Department of Medicine, our researchers collaborate to develop better health care, improved quality of life, and enhanced preventative measures for all patients. Our findings in the laboratory are translated into changes in clinical practice, from bench to bedside.